The Clinical Trials Office (CTO) was organized and implemented as a reflection of the Center leadership's commitment to increasing institutional and multimodality research, and to address the increasingly complex regulatory environment associated with clinical trials. Richard Wheeler, M.D., was recruited in late 1999 to establish and supervise the CTO, which has been supported primarily with institutional funds. The CTO is located on the second floor of HCI adjacent to the outpatient clinics and clinical faculty offices. It functions as a central administrative office for the implementation and conduct of internally and externally funded adult oncology studies. As a proposed clinical shared resource, the CTO is directly responsible to the Clinical Research Executive Committee (CREC). The CTO is administratively responsible for supervising protocol initiation and maintenance, quality control, regulatory compliance, budget development, and protocol educational activities. The CTO currently has 11 study coordinators who assist investigators in patient enrollment, study compliance, and data management. The specific objectives of the CTO are: . To support cancer center investigators with centralized protocol development, initiation, and management. . To assist in the preparation of protocols to the IRB, Clinical Cancer Investigations Committee (CCIC), and other review committees, as required by federal and University of Utah policy. . To process all regulatory documents, including submission of protocol amendments, revisions, adverse events, and annual renewals to the IRB, CCIC, and other applicable regulatory committees. . To negotiate budgets and contracts with study sponsors and the University of Utah Office of Sponsored Projects. . To assist investigators in the enrollment of study subjects. . To screen new patients for protocol eligibility. . To provide quality data to sponsors and ensure study compliance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA042014-18
Application #
7063437
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
18
Fiscal Year
2005
Total Cost
$26,379
Indirect Cost
Name
University of Utah
Department
Type
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Piñas, Germán E; DeSantis, Michael D; Parkinson, John S (2018) Noncritical Signaling Role of a Kinase-Receptor Interaction Surface in the Escherichia coli Chemosensory Core Complex. J Mol Biol 430:1051-1064
Sadler, Jessica B A; Wenzel, Dawn M; Williams, Lauren K et al. (2018) A cancer-associated polymorphism in ESCRT-III disrupts the abscission checkpoint and promotes genome instability. Proc Natl Acad Sci U S A 115:E8900-E8908
Stump, Tammy K; Aspinwall, Lisa G; Kohlmann, Wendy et al. (2018) Genetic Test Reporting and Counseling for Melanoma Risk in Minors May Improve Sun Protection Without Inducing Distress. J Genet Couns 27:955-967
Rambau, Peter F; Vierkant, Robert A; Intermaggio, Maria P et al. (2018) Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. J Pathol Clin Res 4:250-261
Tavtigian, Sean V; Greenblatt, Marc S; Harrison, Steven M et al. (2018) Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med 20:1054-1060
Rogers, R Aaron; Fleming, Aaron M; Burrows, Cynthia J (2018) Unusual Isothermal Hysteresis in DNA i-Motif pH Transitions: A Study of the RAD17 Promoter Sequence. Biophys J 114:1804-1815
Rogers, R Aaron; Fleming, Aaron M; Burrows, Cynthia J (2018) Rapid Screen of Potential i-Motif Forming Sequences in DNA Repair Gene Promoters. ACS Omega 3:9630-9635
Wei, Xiaomu; Calvo-Vidal, M Nieves; Chen, Siwei et al. (2018) Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Res 78:2747-2759
Sample, Danielle C; Samadder, N Jewel; Pappas, Lisa M et al. (2018) Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients. BMC Gastroenterol 18:115
Barrott, Jared J; Illum, Benjamin E; Jin, Huifeng et al. (2018) Paracrine osteoprotegerin and ?-catenin stabilization support synovial sarcomagenesis in periosteal cells. J Clin Invest 128:207-218

Showing the most recent 10 out of 1193 publications